Published Clinical research on medical benefits of Psychedelics
Addiction
Psilocybin Mushrooms - TOBACCO addiction
American Journal of Drug & Alcohol Abuse
Long-term Follow-up of Psilocybin-facilitated Smoking Cessation
PSILOCYBIN MUSHROOMS - TOBACCO ADDICTION
Current Drug Abuse Reviews
Psilocybin-occasioned Mystical Experiences in the Treatment of Tobacco Addiction
PSILOCYBIN MUSHROOMS - TOBACCO ADDICTION
Journal of Psychopharmacology
Pilot Study of the 5-HT2AR Agonist Psilocybin in the Treatment of Tobacco Addiction
AYAHUASCA - Alcoholism & Tobacco Addiction
Frontiers in Psychiatry
Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca
PSILOCYBIN MUSHROOMS - Alcoholism
Frontiers in Pharmacology
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
PSILOCYBIN MUSHROOMS - Opioid ADDICTION
Journal of Psychopharmacology
The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women
IBOGA - OPOID, COcaine ADDICTION
Frontiers in Pharmacology
Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes
IBOGA - OPOID ADDICTION
The American Journal of Drug and Alcohol Abuse
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study
Ayahuasca - substance abuse
Frontiers in Pharmacology
Protocol for Outcome Evaluation of Ayahuasca-Assisted Addiction Treatment: The Case of Takiwasi Center
Mescaline Cacti - Substance abuse
ACS Pharmacology
Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes
Psilocybin Mushrooms, Ayahuasca, Mescaline Cacti - Substance abUse
Frontiers in Psychiatry
Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study